According to the New York Times , a smaller trial found that the drug could also reduce the risk of heart complications in diabetes patients
Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, et al
But, as youll see, it comes with its own set of challenges
Iannitellis supervised plan as outlined
People doing well rarely post Day 147 update: still feeling great, no issues. This creates sampling bias where forums and comment sections overrepresent negative experiences while underrepresenting typical experiences
As of 2024, Medicare Part D plans may cover semaglutide 2.4 mg (Wegovy) when prescribed for its cardiovascular risk reduction indication in eligible patients